Xynomic Pharma, a clinical stage US-China oncology drug development company, announced that its Trials-in-Progress poster discussing the ongoing, potentially pivotal, phase 3 trial of abexinostat plus pazopanib as first- or second-line therapy in patients with locally advanced or metastatic renal cell carcinoma (RCC) will be presented by Dr Rahul Aggarwal of University of California San Francisco, a lead investigator, at the ASCO-Genitourinary Cancers Symposium on February 16, 2019 in San Francisco, California, USA.
Ook interessant voor je
